<DOC>
	<DOCNO>NCT00002199</DOCNO>
	<brief_summary>To compare safety , tolerance , early antiviral activity , durability antiviral response lamivudine ( 3TC ) /zidovudine ( ZDV ) /1592U89 arm versus 3TC/ZDV/indinavir ( IDV ) arm . To determine effect two arm clinical efficacy determine occurrence new CDC , define class B/C event , survival , medical resource utilization , development plasma viral genotypic phenotypic resistance .</brief_summary>
	<brief_title>A Phase III Randomized Double-Blind , Multicenter Study Evaluate Safety Efficacy 3TC/ZDV/1592U89 3TC/ZDV/IDV HIV-1 Infected Antiretroviral Therapy-Naive Subjects .</brief_title>
	<detailed_description>In international study , 550 patient randomize ( 225 per arm ) receive Combivir combination 1592U89 indinavir . If 16 week ( every 8 week thereafter week 48 ) patient HIV-1 RNA &gt; = 400 copies/ml ( PCR two occasion &gt; = 1 week &lt; 4 week apart ) , patient option switch open-label therapy consist indinavir , 1592U89 , Combivir .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Abacavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : GMCSF , GCSF , erythropoietin . Concurrent Treatment : Allowed : Local treatment Kaposi 's sarcoma . Patients must : HIV1 infection document license HIV1 antibody ELISA confirm Western blot detection HIV1 antibody positive HIV1 blood culture . CD4+ cell count &gt; = 100 cells/mm3 within 14 day prior study drug administration . HIV1 RNA &gt; = 10,000 copies/ml within 14 day prior study drug administration . No active diagnosis AIDS accord 1993 Centers Disease Control ( CDC ) AIDS surveillance definition ( exclude CD4+ cell count &lt; 200 cells/mm3 ) . Signed , inform consent parent legal guardian patient 18 year age . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Malabsorption syndrome gastrointestinal dysfunction may interfere drug absorption . Serious medical condition diabetes , congestive heart failure , cardiomyopathy , cardiac dysfunction would compromise safety patient . Concurrent Medication : Excluded : Cytotoxic chemotherapeutic agent . Agents document antiHIV1 activity vitro . Foscarnet . Immunomodulating agent systemic corticosteroid , interleukin , thalidomide , interferon . Terfenadine , astemizole , cisapride , triazolam , midazolam , ergotamine/dihydroergotamine . Concurrent Treatment : Excluded : Radiation therapy . Other investigational treatment . NOTE : Treatments available treatment IND expand access program exception evaluate individually . Patients follow prior condition exclude : History relevant pancreatitis hepatitis last 6 month . Prior Medication : Excluded : Cytotoxic chemotherapeutic agent within 30 day study drug administration . Prior antiretroviral therapy . HIV vaccine dose within 90 day study drug administration . Immunomodulating agent systemic corticosteroid , interleukin , interferon within 30 day study entry . Prior Treatment : Excluded : Radiation therapy within 30 day study drug administration . Current alcohol illicit drug use may interfere patient compliance .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1998</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Drug Resistance , Microbial</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Genotype</keyword>
	<keyword>Phenotype</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>abacavir</keyword>
</DOC>